The Hunter Williams Podcast Survodutide & Mazdutide | The GLP-1/Glucagon Duo That Could Rival Reta
Mar 31, 2026
Deep dive into two rising GLP-1/glucagon dual agonists and how they differ in receptor balance. Trial highlights showing large weight loss and major liver fat reductions. Discussion of metabolic effects of glucagon beyond appetite. Practical talk on dosing, tolerability differences, and choosing the right compound for appetite control versus energy expenditure.
AI Snips
Chapters
Transcript
Episode notes
Why Adding Glucagon Changes GLP Therapy
- GLP-1 and glucagon dual agonists add energy expenditure to appetite suppression.
- Hunter Williams explains glucagon raises resting calorie burn (~200 kcal/day) and drives hepatic fat oxidation distinct from GLP-1 effects.
Mechanisms Behind Glucagon Driven Fat Loss
- Glucagon increases energy expenditure via hepatic fuel cycling and FGF21-mediated thermogenesis.
- Hunter cites acute glucagon infusion raising caloric expenditure ~200 kcal/day and stimulating hepatic beta-oxidation to reduce liver fat.
Mazdutide's Strong Liver Fat Results
- Mazdutide produced massive liver fat reductions and substantial weight loss in trials.
- Hunter reports 80% liver fat reduction at 6 mg/week and up to 21% weight loss at higher doses in non-diabetic trials.